NCT06595238: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 7 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06595238 |
|---|---|
| Title | A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 1, 2024 |
| Completion date | Aug. 8, 2025 |
| Required reporting date | Aug. 8, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |